Merck Patent Gmbh

Emd Lexigen Research Center Corp.

Kymab Limited

Fuji Immunopharmaceuticals Corp.

Abbott Biotech, Inc.

Other

The Scripps Research Institute

Emd Serono Research Center, Inc.

Probiodrug Ag

Institut National De La Sante Et De La Recherche Medicale

Shionogi Bioresearch Corporation

Vivoryon Therapeutics N.v.

Antisoma Research Limited

Merk Patent Gmbh

Merck Patent Gesellschaft MIT Beschraenkter Haftung

Stephen D Gillies

Kin-Ming Lo

Ian Kirby

Jamie Iain Campbell

Miha Kosmac

Volker Germaschewski

Cassandra Van Krinks

Thomas Gallagher

Jeffrey Charles Way

Anita Anne Hamilton

Susan Xiuqi Qian

Nikole Sandy

Yan Lan

Matthew Baker

Stephen Williams

Scott Lauder

Francis Joseph Carr

David A Cheresh

Ralph A Reisfeld

Christa Burger

Pascal Andre Stein

Stephen John Arkinstall

Steve Arkinstall

Mitsunori Ono

E-Chiang Lee

Stephan Schilling

Yumiko Wada

Jens-Ulrich Rahfeld

Graham Carter

Martin Kleinschmidt

John Watkins

Matthew John McCourt

Richard Charles Alfred Sainson

Hiroshi Kitaguchi

Francis J Carr

Yaming Wu

Dan Zhou

Ryoichi Nemori

Thore Hettmann

Yuan Liu

Christel Larbouret

Yaping Sun

André Pelegrin

Pascal André Stein

Holger N Lode

John S Wesolowski, Jr

Cecilia Deantonio

Anke Piechotta

Marian Hanlon

Mohammed Hanif Ali

Jones Tim

Nigel John Watkins

Yue Li

Yukio Sudo

Wojciech Wrona

Sylvia Holden

Joana De Abreu Carvalho

Hanns-Christian Mahler

Nikole Sandy Nee Waddell

John Wesolowski

Xiuqi Qian

Yumiko Jimbo

Nha Huu Vo

Beatrice Brunkhorst

David Azria

Rachael Jane Kimber

Kin Ming Lo

Jeffrey C Way

Tadeusz Warchol

Steven C Degon

Rakesh Verma

Dorothee Kress

Robert Mueller

Stefan Schilling

Thore AO Hettmann

Jeffrey Way

Sylvia A Holden

Stephan G Klinz

The present invention relates to anti-PD-L1 antibodies, bispecific antibodies containing one domain with specificity to PD-L1, and to immunocytokines comprising an anti-PD-L1 antibody fused to a cytokine, such as IL-2. The present invention also provides methods of treatment, uses and pharmaceutical compositions comprising the antibodies, bispecific antibodies and immunocytokines.

Anti-PD-L1 antibodies

The invention relates to humanized and de-immunized antibodies that bind to an epitope at the N-terminus of pyroglutamated amyloid beta (Aβ N3pE) peptide and to preventive and therapeutic treatment of diseases and conditions that are related to accumulation and deposition of amyloid peptides, such as amyloidosis, a group of disorders and abnormalities associated with pyroglutamated amyloid peptide, like Alzheimer's disease, Down's syndrome, cerebral amyloid angiopathy and other related aspects. More specifically, it pertains to the use of monoclonal antibodies of the invention to bind pyroglutamated amyloid beta peptide in plasma, brain, and cerebrospinal fluid to prevent accumulation or to reverse deposition of Aβ N3pE within the brain and in various tissues in the periphery, and to alleviate amyloidosis. The present invention further pertains to diagnostic assays for the diagnosis of amyloidosis using the antibodies of the invention.

Humanized and de-immunized antibodies

Anti-PD-L1 and IL-2 cytokines

Provided are recombinant antibodies comprising one or more peptides fused to the C-terminus of the light chain constant region. Recombinant immunocytokines comprising a cytokine fused to the C-terminus of the light chain constant region are described and shown to be surprisingly active.

Light chain immunoglobulin fusion proteins and methods of use thereof

The present invention relates to antibodies specific for one or more antigens, bispecific antibodies containing one or more domains with specificity to the target(s), and to immunocytokines. The present invention also provides methods of treatment, uses and pharmaceutical compositions comprising the antibodies, bispecific antibodies and immunocytokines.

TIGIT antibodies, encoding nucleic acids and methods of using said antibodies in vivo

The invention relates to humanized antibodies that bind to an epitope at the N-terminus of pyroglutamated amyloid beta (A&#x3b2; N3pE) peptide and to preventive and therapeutic treatment of diseases and conditions that are related to accumulation and deposition of amyloid peptides, such as amyloidosis, a group of disorders and abnormalities associated with pyroglutamated amyloid peptide, like Alzheimer's disease, Down's syndrome, cerebral amyloid angiopathy and other related aspects. More specifically, it pertains to the use of humanized monoclonal antibodies to bind pyroglutamated amyloid beta peptide in plasma, brain, and cerebrospinal fluid to prevent accumulation or to reverse deposition of A&#x3b3; N3pE within the brain and in various tissues in the periphery, and to alleviate amyloidosis. The present invention further pertains to diagnostic assays for the diagnosis of amyloidosis using the humanized antibodies of the invention.

Humanized antibodies

The invention provides modified antibodies directed against GD2 that have diminished complement fixation relative to antibody-dependent, cell-mediated cytotoxicity, which is maintained. The modified antibodies of the invention may be used in the treatment of tumors such as neuroblastoma, glioblastoma, melanoma, small-cell lung carcinoma, B-cell lymphoma, renal carcinoma, retinoblastoma, and other cancers of neuroectodermal origin.

Anti-cancer antibodies with reduced complement fixation

Antibodies and immunocytokines

The invention relates to humanized antibodies that bind to an epitope at the N-terminus of pyroglutamated amyloid beta (A&#x3b2; N3pE) peptide and to preventive and therapeutic treatment of diseases and conditions that are related to accumulation and deposition of amyloid peptides, such as amyloidosis, a group of disorders and abnormalities associated with pyroglutamated amyloid peptide, like Alzheimer's disease, Down's syndrome, cerebral amyloid angiopathy and other related aspects. More specifically, it pertains to the use of humanized monoclonal antibodies to bind pyroglutamated amyloid beta peptide in plasma, brain, and cerebrospinal fluid to prevent accumulation or to reverse deposition of A&#x3b2; N3pE within the brain and in various tissues in the periphery, and to alleviate amyloidosis. The present invention further pertains to diagnostic assays for the diagnosis of amyloidosis using the humanized antibodies of the invention.

Antibodies that bind ICOS (Inducible T cell Co-Stimulator). Therapeutic use of anti-ICOS antibodies for modulating the ratio between regulatory T cells and effector T cells, to stimulate the immune system of patients, including use in treating cancers. Methods of producing anti-ICOS antibodies, including species cross-reactive antibodies, using transgenic knock-out mice.

Anti-ICOS antibodies

The invention relates to the combined use of anti-EGFR antibodies and anti-Her2 antibodies for the treatment of cancer, especially suitable for cancer expressing high levels of the EGFR type and low levels of HER2. The invention refers in particular monoclonal antibody 'trastuzumab' (HERCEPTIN&#xae;) directed against the HER2 receptors the efficacy of which can be significantly increased in vivo when combined with monoclonal antibody 'matuzumab' (hmAB 425, EMD 72000) directed against EGF receptors. The combination treatment is suitable for patients suffering from cancer having said receptor profile, preferably pancreatic cancer.

Combination therapy using anti-EGFR and anti-HER2 antibodies

Growing community of inventors

Hingham, MA, United States of America

Stephen D Gillies